公开(公告)号：US09682137B2

公开(公告)日：2017-06-20

申请号：US14363095

申请日：2012-12-07

Applicant: VIROXIS S.A.S. ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITE PARIS-SUD XI ,  INSTITUT GUSTAVE ROUSSY

Inventor： Thierry Heidmann

IPC: A61K39/12 ,  A61K39/21 ,  C07K14/005

CPC classification number: A61K39/21 ,  A61K39/12 ,  C07K14/005 ,  C12N2740/15022 ,  C12N2740/15034 ,  C12N2740/16122 ,  C12N2740/16134

Abstract: A pharmaceutical composition includes, as active substance a mutated lentiviral ENV protein, substantially devoid of immunosuppressive properties or a variant of the mutated lentiviral ENV protein or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier.

公开(公告)号：US20130149323A1

公开(公告)日：2013-06-13

申请号：US13707885

申请日：2012-12-07

Applicant: Centre National De La Recherche Scientifique ,  Universite Paris-Sud XI ,  Institut Gustave Roussy ,  Viroxis S.A.S.

Inventor： Thierry HEIDMANN

IPC: A61K39/12

CPC classification number: A61K39/12 ,  A61K39/21 ,  C07K7/06 ,  C07K7/08 ,  C07K14/005 ,  C07K14/162 ,  C12N2740/15022 ,  C12N2740/15033 ,  C12N2740/15034 ,  C12N2740/16022 ,  C12N2740/16034 ,  C12N2740/16111 ,  C12N2740/16122 ,  C12N2740/16134

Abstract: A pharmaceutical composition includes, as active substance a mutated lentiviral ENV protein, substantially devoid of immunosuppressive properties or a variant of the mutated lentiviral ENV protein or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier.

Abstract translation: 作为活性物质的药物组合物包括与药学上可接受的载体结合的基本上缺乏免疫抑制性质的突变型慢病毒ENV蛋白或上述蛋白质的片段的突变慢病毒ENV蛋白的活性物质。

公开(公告)号：US09974852B2

公开(公告)日：2018-05-22

申请号：US14896505

申请日：2014-06-06

Applicant: VIROXIS S.A.S. ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT GUSTAVE ROUSSY ,  UNIVERSITE PARIS-SUD XI

Inventor： Thierry Heidmann

IPC: A61K48/00 ,  A61K39/00 ,  C12N15/00 ,  C12N15/63 ,  A61K39/21 ,  A61K39/12 ,  C07K14/005

CPC classification number: A61K39/21 ,  A61K39/12 ,  A61K2039/53 ,  A61K2039/552 ,  A61K2039/572 ,  C07K14/005 ,  C12N2740/15022 ,  C12N2740/15034

Abstract: A pharmaceutical composition includes, as active substance a mutated non-primate lentiviral Env protein having decreased immunosuppressive properties, substantially no immunosuppressive properties or no immunosuppressive properties, or a variant of the mutated lentiviral Env protein, or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier.

公开(公告)号：US20160129107A1

公开(公告)日：2016-05-12

申请号：US14896505

申请日：2014-06-06

Applicant: VIROXIS S.A.S. ,  UNIVERSITE PARIS-SUD XI ,  INSTITUT GUSTAVE ROUSSY ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Inventor： Thierry HEIDMANN

IPC: A61K39/21

CPC classification number: A61K39/21 ,  A61K39/12 ,  A61K2039/53 ,  A61K2039/552 ,  A61K2039/572 ,  C07K14/005 ,  C12N2740/15022 ,  C12N2740/15034

Abstract: A pharmaceutical composition includes, as active substance a mutated non-primate lentiviral Env protein having decreased immunosuppressive properties, substantially no immunosuppressive properties or no immunosuppressive properties, or a variant of the mutated lentiviral Env protein, or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier.

Abstract translation: 药物组合物包括作为活性物质的具有降低的免疫抑制性质的突变的非灵长类慢病毒Env蛋白，基本上没有免疫抑制性质或无免疫抑制性质，或突变慢病毒Env蛋白的变体或上述蛋白质的片段 与药学上可接受的载体。

公开(公告)号：US09636396B2

公开(公告)日：2017-05-02

申请号：US13707885

申请日：2012-12-07

Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITE PARIS-SUD XI ,  INSTITUT GUSTAVE ROUSSY ,  VIROXIS S.A.S.

Inventor： Thierry Heidmann

IPC: A61K39/21 ,  C07K14/16 ,  C07K7/06 ,  C07K7/08 ,  C07K14/005 ,  A61K39/12

CPC classification number: A61K39/12 ,  A61K39/21 ,  C07K7/06 ,  C07K7/08 ,  C07K14/005 ,  C07K14/162 ,  C12N2740/15022 ,  C12N2740/15033 ,  C12N2740/15034 ,  C12N2740/16022 ,  C12N2740/16034 ,  C12N2740/16111 ,  C12N2740/16122 ,  C12N2740/16134

Abstract: A pharmaceutical composition includes, as active substance a mutated lentiviral ENV protein, substantially devoid of immunosuppressive properties or a variant of the mutated lentiviral ENV protein or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier.

公开(公告)号：US20140294880A1

公开(公告)日：2014-10-02

申请号：US14363095

申请日：2012-12-07

Applicant: VIROXIS S.A.S. ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITE PARIS-SUD XI ,  INSTITUT GUSTAVE ROUSSY

Inventor： Thierry Heidmann

IPC: A61K39/21 ,  C07K14/005

CPC classification number: A61K39/21 ,  A61K39/12 ,  C07K14/005 ,  C12N2740/15022 ,  C12N2740/15034 ,  C12N2740/16122 ,  C12N2740/16134

Abstract: A pharmaceutical composition includes, as active substance a mutated lentiviral ENV protein, substantially devoid of immunosuppressive properties or a variant of the mutated lentiviral ENV protein or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier.

Abstract translation: 作为活性物质的药物组合物包括与药学上可接受的载体结合的基本上缺乏免疫抑制性质的突变型慢病毒ENV蛋白或上述蛋白质的片段的突变慢病毒ENV蛋白的活性物质。